Since entering August, pharmaceutical companies have intensively disclosed their 2022 interim reports
.
It can be seen from the report that many pharmaceutical companies have achieved gratifying results
in double growth in revenue and net profit.
In addition, through combing, it is found that increasing investment in R&D innovation has become a common feature
of many pharmaceutical companies.
Increase investment in innovation and research and development, pharmaceutical companies show vitality and potential (Source: Pharmaceutical Network)
For example, Renfu Pharmaceutical recently said in the 2022 semi-annual report that in the first half of the year, Renfu Pharmaceutical achieved double growth in operating income and net profit, increasing by 8.
95% to 10.
535 billion yuan and 140.
63% to 1.
594 billion yuan
, respectively.
Among them, Renfu Pharmaceutical maintained a high investment in the field of R&D and innovation, and in the first half of the year, the R&D investment was 420 million yuan, an increase of 12.
51%
year-on-year.
The 2022 semi-annual report released by Yahong Pharmaceutical also shows that the company continues to increase investment in
research and development and innovation.
The report shows that the scale of R&D of Yahong Pharmaceutical has been expanding, and the core innovation and competitiveness have continued to increase
.
In the first half of 2022, there were 126 R&D personnel, an increase of 38% over the same period of the previous year, with a R&D investment of 93.
049 million yuan, while expanding the Shanghai R&D center and steadily promoting the R&D process
of multiple core pipelines.
The cumulative R&D investment of Huiyu Pharmaceutical in the first half of the year reached 170.
7054 million yuan, an increase of 55.
53% year-on-year, and the proportion of operating income increased to 20.
49%.
In the first half of the year, Hengrui Pharmaceutical's cumulative R&D investment reached 2.
909 billion yuan, an increase of 12.
74% year-on-year, and the proportion of R&D investment in sales revenue increased to 28.
44%
year-on-year.
Kaiyin Technology continued to increase R&D investment based on the independent research and development model and based on the innovative drug research and development platform, with a total R&D investment of 71.
9706 million yuan during the reporting period, accounting for 14.
60% of the operating income, an increase of 82.
92%
year-on-year.
The performance of Yuekang Pharmaceutical in R&D investment is also worthy of attention
.
According to its 2022 semi-annual report, Yuekang Pharmaceutical's R&D expenditure during the reporting period reached 224 million yuan, an increase of 106.
71%
year-on-year.
In the first half of this year, Changchun High-tech's R&D investment also increased by 52.
62%
year-on-year.
It is understood that with the increase of R & D investment of various pharmaceutical companies, enterprises have also made new progress in innovation and research and
development.
For example, Renfu Pharmaceutical said that in terms of product declaration and registration, the company's first-class chemical drug injection of ramazolam besylate (new indications and specifications), three types of chemical drugs memantine hydrochloride extended-release capsules, ibuprofen soft capsules, four types of chemical injection of chorionicin, six types of chemical drugs midazolam injection (new specifications) and other products have been approved
.
Huiyu Pharmaceutical said that as of the end of the reporting period, 2 new projects were established, and a total of 11 innovative drug projects were under research, of which 6 were small molecule drugs and 5 were biological innovative drugs; There are 2 improved new drug projects, and it is expected that 1-2 IND applications
will be submitted before the first half of next year.
Up to now, the company has more than 10 therapeutic drugs in the field of oncology listed and sold in China, of which one is a single product with an annual sales of more than 1 billion yuan and two single products with an annual sales volume of more than 100 million yuan
.
Hengrui Pharmaceutical also said that entering the back end of the research and development chain, the rich innovation results reflect the value of
huge R & D investment.
In the first half of the year, Hengrui Pharmaceutical developed more than 60 innovative drugs and carried out more than 260 clinical studies
at home and abroad.
The progress of clinical trials of innovative drugs has accelerated, and the self-developed AR inhibitor rivirus tablets have been approved for marketing, and the number of innovative drugs on the market has increased to 11
.
Four products entered the marketing declaration stage, including PD-L1 inhibitor Adebelimumab injection, HR20033 tablets, SHR8008 capsules, SHR8554 injection, the treatment areas involving cancer, diabetes, anti-infection, analgesia and so on
.
In addition, there are 29 clinical studies of more than 20 products such as carellizumab, pirroltinib, apatinib, SHR0302 and so on
.
Kain Technology said that in terms of new product development and registration declaration, a number of research projects have made significant progress, such as the phase III clinical trial of KW-001 for the treatment of low-replication chronic HBV infection has completed the enrollment of all subjects; KW-027 has completed preclinical pilot production; Non-clinical pharmacology, toxicology, efficacy related research is being carried out; KW-020 Submit a supplementary application and declare a consistency evaluation; KW-045 has filed a Pre-IND application
.
Based on the investment in innovative research and development, many pharmaceutical companies have shown vitality and potential
in drug research and development.
It is understood that in recent years, under the impetus of favorable policies in China, the field of innovative drugs has ushered in rapid development
.
Some data predict that the scale of China's biological drug market is expected to reach 1,319.
8 billion yuan by 2030, and the compound annual growth rate from 2018 to 2030 is expected to be 14.
4%, and there is still huge room
for improvement in the overall market of innovative drugs.
